Skip to main content

You are here:

An International, Multicentre, Randomised Controlled Pragmatic Trial of Mirtazapine to alleviate Breathlessness in Palliative and End of Life Care.

The trial is to assess the effectiveness and cost-effectiveness of mirtazapine for the reduction of patient-reported chronic or refractory breathlessness and quality of life in patients with COPD or ILD and at end of life, and on the caregiver burden, quality of life and experience of their lay caregivers and close family members.

Key Eligibility Criteria

Diagnosed with:

  •  Chronic obstructive pulmonary disease (COPD), and/ori
  •  Interstitial lung disease (ILD), including chronic fibrotic lung disease following SARS-CoV-2 infection

Breathlessness severity: Modified MRC (mMRC) breathlessness scale of:

  •  Grade 3 (I stop for breath after walking about 100 yards or after a few minutes on level ground) or
  • Grade 4 (I am too breathless to leave the house, or I am breathless when dressing or undressing)
Therapeutic Area
Respiratory Medicine
Type of Study
Clinical trial
Study Status
Open Recruiting
Kings College London
Principal Investigator
Dr Emer Kelly